Search for: "Bhaven Sampat"
Results 41 - 60
of 63
Sorted by Relevance
|
Sort by Date
15 Apr 2018, 2:14 pm
For more information, see here.ArticlesA new article by academics Bhaven Sampat and Kenneth Shadlen looks at pharmaceutical patents in India. [read post]
2 Mar 2009, 7:03 am
Bhaven Sampat, a professor at Columbia University and co-author of the article "What To Do About Bad Patents", states that patent examiners are only citing non-patent prior art 10 percent of the time. [read post]
24 Aug 2007, 10:37 am
Rev. 601 (2005) -->Thanks to John Allison, Chris Cotropia, Rochelle Dreyfuss, Nathan Durrance, Hank Greely, Rose Hagan, David Jaffer, Joseph Mallen, Greg Mandel, Michael Martin, Judge Margaret McKeown, John Miller, Craig Nard, Matt Powers, Bhaven Sampat, Madhavi Sunder, Hal Wegner, and participants at programs at Stanford Law School, the University of San Diego School of Law, the U.C. [read post]
18 Jan 2011, 6:29 pm
: An Empirical Analysis of ‘Secondary’ Pharmaceutical Patents, by Amy Kapczynski, Chan Park (UNITAID), and Bhaven Sampat (Columbia School of Public Health), is a fascinating example of the great results that transpire when a law professor, empirical researcher, and public health and policy expert decide to study a particular issue. [read post]
11 Jun 2009, 11:48 pm
Lemley, Doug Lichtman & Bhaven Sampat, What To Do About Bad Patents, Regulation, Winter 2005-06, at 10. [read post]
11 Mar 2014, 7:53 am
There is also some literature on financially supporting innovation through direct government spending with grants or procurement contracts, and our conference will include three new papers in this area by Bhaven Sampat, Camilla Hrdy, and Jim Bessen. [read post]
24 Oct 2014, 9:46 am
Not sure that this measures follow-on innovation; these don’t require licenses and may just reflect changes in competition.Excellent empirical work; leaves open questions.Stefan Bechtold (ETH Zurich)Topic: The Effects of Patents on Scientific Research, Commenting on: Bhaven Sampat & Heidi L. [read post]
4 Feb 2012, 6:01 pm
See Cotropia, Christopher Anthony, Lemley, Mark A. and Sampat, Bhaven N., Do Applicant Patent Citations Matter? [read post]
4 Feb 2012, 6:01 pm
See Cotropia, Christopher Anthony, Lemley, Mark A. and Sampat, Bhaven N., Do Applicant Patent Citations Matter? [read post]
1 Jul 2008, 4:25 am
Bhaven Sampat, a professor at Columbia University and co-author of the article "What To Do About Bad Patents", states that patent examiners are only citing non-patent prior art 10 percent of the time. [read post]
17 Oct 2009, 6:51 am
Disadvantage:Mark Lemley, Douglas Lichtman and Bhaven N. [read post]
2 Apr 2008, 9:46 am
Lemley & Bhaven Sampat, Is the Patent Office a Rubber Stamp? [read post]
13 Aug 2020, 8:09 am
As Professor Bhaven Sampat has recently explained, this division emerged from a debate on science and technology governance at the end of WWII, when Vannevar Bush’s vision triumphed over that of Senator Harley Kilgore. [read post]
22 Apr 2012, 9:30 pm
Bhaven Sampat, PhD, is an assistant professor in the Department of Health Policy and Management at Columbia's Mailman School of Public Health. [read post]
14 Nov 2007, 10:21 pm
":Law professor Mark Lemley, Douglas Lichtman, and Bhaven Sampat wrote a paper titled "What to do About Bad Patents," that reads like a blueprint for Obama's patent agenda. [read post]
23 Feb 2010, 2:48 pm
Topics include: Quality and Pendency: Drilling Down to Backlog, Deferred Examination, Patent Worksharing and Other Integers to Achieve Primary Goals led by Hal Wegner The Role of Applicant Incentives in Patent Office Reform led by Dennis Crouch Patent Examination Policy and the Social Costs of Examiner Allowance and Rejection Errors led by Ron Katznelson Examiner Characteristics and the Patent Grant Rate led by Mark Lemley & Bhaven Sampat … [read post]
3 Feb 2019, 7:44 am
If you are interested in the more direct costs of developing a specific new drug, however, most of the price is still being paid by the private sector.To illustrate the distinction between direct and indirect influence: Bhaven Sampat and Frank Lichtenberg found that of drugs approved by the FDA from 1998 to 2005, 9% of all drugs and 17% of "priority-review" drugs (those reflecting "significant improvements") have at least one public-sector patent (i.e., a patent… [read post]
7 Oct 2013, 2:39 pm
In Lee's telling, this relationship is characterized by two parallel developments: increased use of patents by universities, on the one hand, and "internalization" of universities and university research into patent law, on the other.Bayh-Dole and the changing position of universities towards patenting has been covered by scholars like Rebecca Eisenberg, Bhaven Sampat, David Mowery, Richard Nelson, and Arti Rai. [read post]
2 Nov 2009, 1:41 am
(IP finance) US General - Decisions PepsiCo's $1.2 billion court no-show in trade secrets misappropriation case brought in connection with AquaFina bottled water (IPKat) Adequately indentifying trade secrets in California trade secret misappropriation litigation: Brescia v Angelin (JIPLP) US Patent Reform Patent 'reform' may happen this year, after all (Patent Docs) US Patents Study conducted by Stuart J H Graham and Dietmar Harhoff concludes US would benefit from EPO-style opposition… [read post]
2 Nov 2009, 1:41 am
(IP finance) US General – Decisions PepsiCo’s $1.2 billion court no-show in trade secrets misappropriation case brought in connection with AquaFina bottled water (IPKat) Adequately indentifying trade secrets in California trade secret misappropriation litigation: Brescia v Angelin (JIPLP) US Patent Reform Patent ‘reform’ may happen this year, after all (Patent Docs) US Patents Study conducted by Stuart J H Graham and Dietmar… [read post]
